Tags

Type your tag names separated by a space and hit enter

Cinacalcet may reduce arterial stiffness in patients with chronic renal disease and secondary hyperparathyroidism - results of a small-scale, prospective, observational study.
Clin Nephrol. 2011 Mar; 75(3):181-7.CN

Abstract

AIMS

This study evaluated the impact of cinacalcet on arterial stiffness, determined by pulse wave velocity (PWV), in patients with chronic renal disease and secondary hyperparathyroidism (SHPT).

PATIENTS AND METHODS

This prospective, observational study included, SHPT patients with chronic renal disease on dialysis undergoing cinacalcet treatment with a follow-up of 12 months.

RESULTS

21 patients, 62% males, with a mean age of 51.3 years (± 18.0) were included. Cinacalcet was given for at least a year with a mean daily dose of 35 mg (range 30-60 mg). Aortic PWV significantly decreased after 12 months of cinacalcet treatment (9.35 ± 1.83 m/sg vs. 8.66 ± 1.86 m/sg; p = 0.030). Additionally, there was a notable reduction trend in the left ventricular mass index (166.6 ± 39.4 g/m² vs. 156.1 ± 31.8 g/m²), although it did not achieve statistical significance (p = 0.063). Alkaline phosphatase and PTH were significantly decreased during the study. However, serum calcium, phosphorus and blood pressure remained stable.

CONCLUSION

The results of this study support the possibility that cinacalcet reduces arterial stiffness of SHPT patients with chronic renal disease after 12 months of treatment. Prospective, randomized clinical trials are needed to confirm these preliminary findings.

Links

Publisher Full Text

Authors+Show Affiliations

Bonet J
Nephrology Department, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Ctra. De Can Ruti, s/n. 08916 Badalona, Barcelona, Spain. Jbonet.germanstrias@gencat.cat
Bayés B
No affiliation info available
Fernández-Crespo P
No affiliation info available
Casals M
No affiliation info available
López-Ayerbe J
No affiliation info available
Romero R
No affiliation info available

MeSH

AdultAgedAlkaline PhosphataseAortaAortic DiseasesBiomarkersBlood PressureCalcimimetic AgentsCalciumCinacalcetElasticityFemaleHumansHyperparathyroidism, SecondaryHypertrophy, Left VentricularKidney Failure, ChronicMaleMiddle AgedNaphthalenesParathyroid HormonePhosphorusProspective StudiesPulsatile FlowRenal DialysisSpainStroke VolumeTime FactorsTreatment OutcomeVentricular Function, Left

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

21329627

Citation

Bonet, J, et al. "Cinacalcet May Reduce Arterial Stiffness in Patients With Chronic Renal Disease and Secondary Hyperparathyroidism - Results of a Small-scale, Prospective, Observational Study." Clinical Nephrology, vol. 75, no. 3, 2011, pp. 181-7.
Bonet J, Bayés B, Fernández-Crespo P, et al. Cinacalcet may reduce arterial stiffness in patients with chronic renal disease and secondary hyperparathyroidism - results of a small-scale, prospective, observational study. Clin Nephrol. 2011;75(3):181-7.
Bonet, J., Bayés, B., Fernández-Crespo, P., Casals, M., López-Ayerbe, J., & Romero, R. (2011). Cinacalcet may reduce arterial stiffness in patients with chronic renal disease and secondary hyperparathyroidism - results of a small-scale, prospective, observational study. Clinical Nephrology, 75(3), 181-7.
Bonet J, et al. Cinacalcet May Reduce Arterial Stiffness in Patients With Chronic Renal Disease and Secondary Hyperparathyroidism - Results of a Small-scale, Prospective, Observational Study. Clin Nephrol. 2011;75(3):181-7. PubMed PMID: 21329627.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cinacalcet may reduce arterial stiffness in patients with chronic renal disease and secondary hyperparathyroidism - results of a small-scale, prospective, observational study. AU - Bonet,J, AU - Bayés,B, AU - Fernández-Crespo,P, AU - Casals,M, AU - López-Ayerbe,J, AU - Romero,R, PY - 2011/2/19/entrez PY - 2011/2/19/pubmed PY - 2011/4/20/medline SP - 181 EP - 7 JF - Clinical nephrology JO - Clin Nephrol VL - 75 IS - 3 N2 - AIMS: This study evaluated the impact of cinacalcet on arterial stiffness, determined by pulse wave velocity (PWV), in patients with chronic renal disease and secondary hyperparathyroidism (SHPT). PATIENTS AND METHODS: This prospective, observational study included, SHPT patients with chronic renal disease on dialysis undergoing cinacalcet treatment with a follow-up of 12 months. RESULTS: 21 patients, 62% males, with a mean age of 51.3 years (± 18.0) were included. Cinacalcet was given for at least a year with a mean daily dose of 35 mg (range 30-60 mg). Aortic PWV significantly decreased after 12 months of cinacalcet treatment (9.35 ± 1.83 m/sg vs. 8.66 ± 1.86 m/sg; p = 0.030). Additionally, there was a notable reduction trend in the left ventricular mass index (166.6 ± 39.4 g/m² vs. 156.1 ± 31.8 g/m²), although it did not achieve statistical significance (p = 0.063). Alkaline phosphatase and PTH were significantly decreased during the study. However, serum calcium, phosphorus and blood pressure remained stable. CONCLUSION: The results of this study support the possibility that cinacalcet reduces arterial stiffness of SHPT patients with chronic renal disease after 12 months of treatment. Prospective, randomized clinical trials are needed to confirm these preliminary findings. SN - 0301-0430 UR - https://wwww.unboundmedicine.com/medline/citation/21329627/Cinacalcet_may_reduce_arterial_stiffness_in_patients_with_chronic_renal_disease_and_secondary_hyperparathyroidism___results_of_a_small_scale_prospective_observational_study_ L2 - http://www.dustri.com/nc/journals-in-english.html?artId=8440 DB - PRIME DP - Unbound Medicine ER -